|
US8101799B2
(en)
|
2005-07-21 |
2012-01-24 |
Ardea Biosciences |
Derivatives of N-(arylamino) sulfonamides as inhibitors of MEK
|
|
AU2006272837B2
(en)
*
|
2005-07-21 |
2012-08-23 |
Ardea Biosciences, Inc. |
N-(arylamino)-sulfonamide inhibitors of MEK
|
|
US7919598B2
(en)
*
|
2006-06-28 |
2011-04-05 |
Bristol-Myers Squibb Company |
Crystal structures of SGLT2 inhibitors and processes for preparing same
|
|
JO2985B1
(ar)
*
|
2006-12-20 |
2016-09-05 |
Takeda Pharmaceuticals Co |
مثبطات كينازmapk/erk
|
|
ES2320955B1
(es)
|
2007-03-02 |
2010-03-16 |
Laboratorios Almirall S.A. |
Nuevos derivados de 3-((1,2,4)triazolo(4,3-a)piridin-7-il)benzamida.
|
|
WO2008115890A2
(en)
|
2007-03-19 |
2008-09-25 |
Takeda Pharmaceutical Company Limited |
Mapk/erk kinase inhibitors
|
|
ES2329639B1
(es)
|
2007-04-26 |
2010-09-23 |
Laboratorios Almirall S.A. |
Nuevos derivados de 4,8-difenilpoliazanaftaleno.
|
|
US8569378B2
(en)
|
2007-07-20 |
2013-10-29 |
Toshiyuki Sakai |
p27 protein inducer
|
|
WO2009064675A1
(en)
*
|
2007-11-12 |
2009-05-22 |
Takeda Pharmaceutical Company Limited |
Mapk/erk kinase inhibitors
|
|
US20090246198A1
(en)
*
|
2008-03-31 |
2009-10-01 |
Takeda Pharmaceutical Company Limited |
Mapk/erk kinase inhibitors and methods of use thereof
|
|
EP2108641A1
(en)
|
2008-04-11 |
2009-10-14 |
Laboratorios Almirall, S.A. |
New substituted spiro[cycloalkyl-1,3'-indo]-2'(1'H)-one derivatives and their use as p38 mitogen-activated kinase inhibitors
|
|
EP2113503A1
(en)
|
2008-04-28 |
2009-11-04 |
Laboratorios Almirall, S.A. |
New substituted indolin-2-one derivatives and their use as p39 mitogen-activated kinase inhibitors
|
|
UA103319C2
(en)
|
2008-05-06 |
2013-10-10 |
Глаксосмитклайн Ллк |
Thiazole- and oxazole-benzene sulfonamide compounds
|
|
US8993630B2
(en)
|
2008-11-10 |
2015-03-31 |
Bayer Intellectual Property Gmbh |
Substituted sulphonamido phenoxybenzamides
|
|
ES2548141T3
(es)
|
2008-11-20 |
2015-10-14 |
Glaxosmithkline Llc |
Compuestos químicos
|
|
US9084781B2
(en)
|
2008-12-10 |
2015-07-21 |
Novartis Ag |
MEK mutations conferring resistance to MEK inhibitors
|
|
BRPI1013561A8
(pt)
*
|
2009-03-26 |
2015-09-22 |
Mapi Pharma Ltd |
processo para a preparação de alogliptina
|
|
CN101619063B
(zh)
*
|
2009-06-02 |
2011-08-10 |
华中师范大学 |
具有抗肿瘤活性的3,7,8-多取代吡啶并[4,3-d]嘧啶衍生物及制备
|
|
WO2011031308A1
(en)
*
|
2009-09-09 |
2011-03-17 |
Cytokinetics, Incorporated |
Novel combinations
|
|
BR112012006485A2
(pt)
*
|
2009-09-23 |
2015-09-08 |
Glaxosmithkline Llc |
combinação
|
|
CN102770026B
(zh)
*
|
2009-09-23 |
2015-04-01 |
葛兰素史密斯克莱有限责任公司 |
组合
|
|
BR112012006968A2
(pt)
*
|
2009-09-28 |
2019-09-24 |
Glaxosmithkline Llc |
combinação
|
|
US8835450B2
(en)
*
|
2009-10-08 |
2014-09-16 |
Glaxosmithkline Llc |
Combination of inhibitor of B-Raf and an inhibitor of Akt in the treatment of cancer
|
|
ME03497B
(me)
*
|
2009-10-16 |
2020-04-20 |
Novartis Ag |
Kombinacija koja sadrži inhibitor mek i inhibitor b-raf
|
|
WO2011047795A1
(en)
|
2009-10-21 |
2011-04-28 |
Bayer Schering Pharma Aktiengesellschaft |
Substituted benzosulphonamides
|
|
WO2011047796A1
(en)
|
2009-10-21 |
2011-04-28 |
Bayer Schering Pharma Aktiengesellschaft |
Substituted halophenoxybenzamide derivatives
|
|
WO2011047788A1
(en)
|
2009-10-21 |
2011-04-28 |
Bayer Schering Pharma Aktiengesellschaft |
Substituted benzosulphonamides
|
|
US20120283279A1
(en)
*
|
2009-11-17 |
2012-11-08 |
Glaxosmithkline Llc |
Combination
|
|
AU2011221227B2
(en)
|
2010-02-25 |
2015-07-09 |
Dana-Farber Cancer Institute, Inc. |
BRAF mutations conferring resistance to BRAF inhibitors
|
|
KR20120139767A
(ko)
|
2010-03-09 |
2012-12-27 |
더 브로드 인스티튜트, 인코퍼레이티드 |
1차 암 요법에 대한 저항성을 갖는 또는 발달시키는 환자에서 암을 진단 및 치료하는 방법
|
|
BR112012024380A2
(pt)
|
2010-03-25 |
2015-09-15 |
Glaxosmithkline Llc |
compostos químicos
|
|
UY33288A
(es)
*
|
2010-03-25 |
2011-10-31 |
Glaxosmithkline Llc |
Derivados de indolina inhibidores de la proteina quinasa r del reticulo endoplasmatico
|
|
RU2589696C2
(ru)
*
|
2010-04-13 |
2016-07-10 |
Новартис Аг |
КОМБИНАЦИЯ, ВКЛЮЧАЮЩАЯ ИНГИБИТОР ЦИКЛИНЗАВИСИМОЙ КИНАЗЫ 4 ИЛИ ЦИКЛИНЗАВИСИМОЙ КИНАЗЫ 6 (CDK4/6) И ИНГИБИТОР mTOR, ДЛЯ ЛЕЧЕНИЯ РАКА
|
|
ES2530755T3
(es)
|
2010-05-21 |
2015-03-05 |
Glaxosmithkline Llc |
Terapia de combinación para el tratamiento del cáncer
|
|
UA112517C2
(uk)
|
2010-07-06 |
2016-09-26 |
Новартіс Аг |
Тетрагідропіридопіримідинові похідні
|
|
EP2608790A4
(en)
|
2010-08-26 |
2014-04-02 |
Glaxosmithkline Llc |
PHARMACEUTICAL COMBINATION OF A VEGFR-INHIBITOR AND A MEK-INHIBITOR FOR THE TREATMENT OF CANCER
|
|
CN103282351A
(zh)
|
2010-10-29 |
2013-09-04 |
拜耳知识产权有限责任公司 |
取代的苯氧基吡啶
|
|
CN102020651B
(zh)
|
2010-11-02 |
2012-07-18 |
北京赛林泰医药技术有限公司 |
6-芳基氨基吡啶酮甲酰胺mek抑制剂
|
|
WO2012061683A2
(en)
*
|
2010-11-05 |
2012-05-10 |
Glaxosmithkline Llc |
Methods for treating cancer
|
|
US20130231346A1
(en)
*
|
2010-11-17 |
2013-09-05 |
Glaxosmithkline Intellectual Property (No.2) Limited |
Methods of treating cancer
|
|
AU2011329666A1
(en)
*
|
2010-11-19 |
2013-05-30 |
Glaxosmithkline Intellectual Property (No.2) Limited |
Method of treatment with BRaf inhibitor
|
|
EP2654755B1
(en)
*
|
2010-12-20 |
2016-08-17 |
Novartis AG |
Combination therapy comprising Gemcitabine for the treatment of pancreatic cancer
|
|
TWI505828B
(zh)
|
2010-12-20 |
2015-11-01 |
葛蘭素史克智慧財產（第二）有限公司 |
新穎醫藥組成物
|
|
US8754114B2
(en)
|
2010-12-22 |
2014-06-17 |
Incyte Corporation |
Substituted imidazopyridazines and benzimidazoles as inhibitors of FGFR3
|
|
WO2013019620A2
(en)
*
|
2011-07-29 |
2013-02-07 |
Glaxosmithkline Llc |
Method of treating cancer using combination of braf inhibitor, mek inhibitor, and anti-ctla-4 antibody
|
|
JP6238459B2
(ja)
|
2011-08-01 |
2017-11-29 |
ジェネンテック， インコーポレイテッド |
Ｐｄ−１軸結合アンタゴニストとｍｅｋ阻害剤を使用する癌の治療方法
|
|
US9675595B2
(en)
|
2011-08-31 |
2017-06-13 |
Novartis Ag |
Synergistic combinations of PI3K- and MEK-inhibitors
|
|
PT2790705T
(pt)
|
2011-12-15 |
2018-01-24 |
Novartis Ag |
Utilização de inibidores da atividade ou função de pi3k
|
|
PE20141974A1
(es)
*
|
2012-03-14 |
2014-12-12 |
Lupin Ltd |
Compuestos de heterociclilo
|
|
WO2013169858A1
(en)
|
2012-05-08 |
2013-11-14 |
The Broad Institute, Inc. |
Diagnostic and treatment methods in patients having or at risk of developing resistance to cancer therapy
|
|
DK3176170T3
(en)
|
2012-06-13 |
2019-01-28 |
Incyte Holdings Corp |
SUBSTITUTED TRICYCLIC RELATIONS AS FGFR INHIBITORS
|
|
US9388185B2
(en)
|
2012-08-10 |
2016-07-12 |
Incyte Holdings Corporation |
Substituted pyrrolo[2,3-b]pyrazines as FGFR inhibitors
|
|
PL2892535T3
(pl)
|
2012-09-04 |
2022-01-31 |
Novartis Ag |
Sposób leczenia adjuwantowego raka
|
|
CA2889530A1
(en)
*
|
2012-10-25 |
2014-05-01 |
Glaxosmithkline Llc |
Combination
|
|
PL2925366T3
(pl)
|
2012-11-29 |
2018-08-31 |
Novartis Ag |
Kombinacje farmaceutyczne
|
|
US20150328320A1
(en)
|
2012-11-30 |
2015-11-19 |
Glaxosmithkline Llc |
Novel Pharmaceutical Composition
|
|
US9266892B2
(en)
|
2012-12-19 |
2016-02-23 |
Incyte Holdings Corporation |
Fused pyrazoles as FGFR inhibitors
|
|
EP2752191A1
(en)
|
2013-01-07 |
2014-07-09 |
Sanofi |
Compositions and methods using hdm2 antagonist and mek inhibitor
|
|
JP2016504409A
(ja)
|
2013-01-09 |
2016-02-12 |
グラクソスミスクライン、インテレクチュアル、プロパティー、ナンバー２、リミテッドＧｌａｘｏｓｍｉｔｈｋｌｉｎｅ Ｉｎｔｅｌｌｅｃｔｕａｌ Ｐｒｏｐｅｒｔｙ Ｎｏ．２ Ｌｉｍｉｔｅｄ |
組合せ
|
|
US10139415B2
(en)
|
2013-02-27 |
2018-11-27 |
Daiichi Sankyo Company, Limited |
Method for predicting responsiveness to compound inhibiting MAPK signal transduction pathway
|
|
CA3130452C
(en)
|
2013-04-19 |
2023-10-31 |
Incyte Holdings Corporation |
Bicyclic heterocycles as fgfr inhibitors
|
|
AR096433A1
(es)
|
2013-05-28 |
2015-12-30 |
Glaxosmithkline Intellectual Property (No 2) Ltd |
Método de tratamiento del cáncer y uso
|
|
SG11201509742QA
(en)
|
2013-06-03 |
2015-12-30 |
Novartis Ag |
Combinations of an anti-pd-l1 antibody and a mek inhibitor and/or a braf inhibitor
|
|
WO2015056180A1
(en)
|
2013-10-15 |
2015-04-23 |
Glaxosmithkline Intellectual Property (No.2) Limited |
Indoline derivatives as inhibitors of perk
|
|
PT3061747T
(pt)
*
|
2013-10-25 |
2021-05-04 |
Shanghai hengrui pharmaceutical co ltd |
Derivados pirídicos de cetona, método para preparar os mesmos e aplicação farmacêutica dos mesmos
|
|
WO2015059677A1
(en)
|
2013-10-26 |
2015-04-30 |
Glaxosmithkline Intellectual Property (No.2) Limited |
Methods of treating cancer
|
|
CN104918937B
(zh)
*
|
2013-12-06 |
2016-09-14 |
杭州普晒医药科技有限公司 |
曲美替尼及其溶剂化物的晶型、其制备方法、含有它们的药物组合物及其用途
|
|
EP3079698A1
(en)
|
2013-12-12 |
2016-10-19 |
Novartis AG |
Combinations of trametinib, panitumumab and dabrafenib for the treatment of cancer
|
|
JOP20200094A1
(ar)
|
2014-01-24 |
2017-06-16 |
Dana Farber Cancer Inst Inc |
جزيئات جسم مضاد لـ pd-1 واستخداماتها
|
|
JOP20200096A1
(ar)
|
2014-01-31 |
2017-06-16 |
Children’S Medical Center Corp |
جزيئات جسم مضاد لـ tim-3 واستخداماتها
|
|
EP2913048A1
(en)
*
|
2014-02-27 |
2015-09-02 |
ratiopharm GmbH |
Pharmaceutical composition comprising trametinib
|
|
AU2015229103C9
(en)
|
2014-03-14 |
2020-11-26 |
Immutep S.A.S |
Antibody molecules to LAG-3 and uses thereof
|
|
AR101210A1
(es)
|
2014-07-15 |
2016-11-30 |
Genentech Inc |
Métodos de tratamiento de cáncer usando antagonistas de unión al eje pd-1 e inhibidores de mek
|
|
WO2016009306A1
(en)
|
2014-07-15 |
2016-01-21 |
Lupin Limited |
Heterocyclyl compounds as mek inhibitors
|
|
WO2016035008A1
(en)
|
2014-09-04 |
2016-03-10 |
Lupin Limited |
Pyridopyrimidine derivatives as mek inhibitors
|
|
RU2718914C2
(ru)
|
2014-09-13 |
2020-04-15 |
Новартис Аг |
Сочетанные способы лечения с использованием ингибиторов alk
|
|
ES2774448T3
(es)
|
2014-10-03 |
2020-07-21 |
Novartis Ag |
Terapias de combinación
|
|
WO2016055935A1
(en)
|
2014-10-06 |
2016-04-14 |
Glaxosmithkline Intellectual Property (No.2) Limited |
Combination of lysine-specific demethylase 1 inhibitor and thrombopoietin agonist
|
|
CU20170052A7
(es)
|
2014-10-14 |
2017-11-07 |
Dana Farber Cancer Inst Inc |
Moléculas de anticuerpo que se unen a pd-l1
|
|
WO2016059602A2
(en)
|
2014-10-16 |
2016-04-21 |
Glaxo Group Limited |
Methods of treating cancer and related compositions
|
|
US10851105B2
(en)
|
2014-10-22 |
2020-12-01 |
Incyte Corporation |
Bicyclic heterocycles as FGFR4 inhibitors
|
|
WO2016100882A1
(en)
|
2014-12-19 |
2016-06-23 |
Novartis Ag |
Combination therapies
|
|
MX373169B
(es)
|
2015-02-20 |
2020-04-24 |
Incyte Holdings Corp |
Heterociclos bicíclicos como inhibidores de receptores del factor de crecimiento fibroblástico (fgfr).
|
|
MA41551A
(fr)
|
2015-02-20 |
2017-12-26 |
Incyte Corp |
Hétérocycles bicycliques utilisés en tant qu'inhibiteurs de fgfr4
|
|
US9580423B2
(en)
|
2015-02-20 |
2017-02-28 |
Incyte Corporation |
Bicyclic heterocycles as FGFR4 inhibitors
|
|
JP2016155776A
(ja)
*
|
2015-02-24 |
2016-09-01 |
学校法人兵庫医科大学 |
抗腫瘍効果増強剤および抗腫瘍剤
|
|
CZ2015278A3
(cs)
|
2015-04-24 |
2016-11-02 |
Zentiva, K.S. |
Krystalické formy trametinibu
|
|
EP3878465A1
(en)
|
2015-07-29 |
2021-09-15 |
Novartis AG |
Combination therapies comprising antibody molecules to tim-3
|
|
DK3317301T3
(da)
|
2015-07-29 |
2021-06-28 |
Immutep Sas |
Kombinationsterapier omfattende antistofmolekyler mod lag-3
|
|
US20180222982A1
(en)
|
2015-07-29 |
2018-08-09 |
Novartis Ag |
Combination therapies comprising antibody molecules to pd-1
|
|
JP2018526377A
(ja)
|
2015-08-28 |
2018-09-13 |
ノバルティス アーゲー |
がんを治療するための、任意にｐｉ３ｋ阻害剤のｂｙｌ７１９を更に含む、ｃｄｋ４／６阻害剤のｌｅｅ０１１とｍｅｋ１／２阻害剤トラメチニブの組み合わせ物
|
|
AU2016314082B2
(en)
|
2015-08-28 |
2019-07-25 |
Novartis Ag |
Mdm2 inhibitors and combinations thereof
|
|
LT3370768T
(lt)
|
2015-11-03 |
2022-05-25 |
Janssen Biotech, Inc. |
Antikūnai, specifiškai surišantys pd-1, ir jų panaudojimas
|
|
RU2605400C1
(ru)
*
|
2015-11-13 |
2016-12-20 |
ЗАО "Р-Фарм" |
ПРОИЗВОДНЫЕ 1-(3-АМИНОФЕНИЛ)-6,8-ДИМЕТИЛ-5-(4-ИОД-2-ФТОР-ФЕНИЛАМИНО)-3-ЦИКЛОПРОПИЛ-1H,6H-ПИРИДО[4,3-d]ПИРИМИДИН-2,4,7-ТРИОНА В КАЧЕСТВЕ ИНГИБИТОРОВ МЕК1/2
|
|
WO2017098421A1
(en)
|
2015-12-08 |
2017-06-15 |
Glaxosmithkline Intellectual Property Development Limited |
Benzothiadiazine compounds
|
|
KR20180088907A
(ko)
|
2015-12-17 |
2018-08-07 |
노파르티스 아게 |
Pd-1에 대한 항체 분자 및 그의 용도
|
|
US11883404B2
(en)
|
2016-03-04 |
2024-01-30 |
Taiho Pharmaceuticals Co., Ltd. |
Preparation and composition for treatment of malignant tumors
|
|
US11975002B2
(en)
|
2016-03-04 |
2024-05-07 |
Taiho Pharmaceutical Co., Ltd. |
Preparation and composition for treatment of malignant tumors
|
|
WO2017153952A1
(en)
|
2016-03-10 |
2017-09-14 |
Glaxosmithkline Intellectual Property Development Limited |
5-sulfamoyl-2-hydroxybenzamide derivatives
|
|
WO2018051306A1
(en)
|
2016-09-19 |
2018-03-22 |
Novartis Ag |
Therapeutic combinations comprising a raf inhibitor and a erk inhibitor
|
|
RU2627692C1
(ru)
*
|
2016-10-10 |
2017-08-10 |
Закрытое акционерное общество "Р-Фарм" (ЗАО "Р-Фарм") |
N-{ 3-[3-циклопропил-5-(2-фторо-4-иодофениламино)-6,8-диметил-2,4,7-триоксо-3,4,6,7-тетрагидро-2Н-пиридо[4,3-d]пиримидин-1-ил]-фенил} -циклопропанкарбоксамида диметилсульфоксида сольват в качестве ингибитора МЕК1/2
|
|
CN107970246B
(zh)
*
|
2016-10-21 |
2020-08-28 |
中山大学 |
非甾体类抗炎药在提高肿瘤细胞对酪氨酸激酶抑制剂的敏感性中的应用
|
|
WO2018092064A1
(en)
|
2016-11-18 |
2018-05-24 |
Novartis Ag |
Combinations of mdm2 inhibitors and bcl-xl inhibitors
|
|
EP3425390B1
(en)
|
2016-11-25 |
2020-12-23 |
Genuv Inc. |
Composition for promoting differentiation of and protecting neural stem cells and method for inducing neural regeneration using same
|
|
KR20190090824A
(ko)
|
2016-12-01 |
2019-08-02 |
글락소스미스클라인 인털렉츄얼 프로퍼티 디벨로프먼트 리미티드 |
암을 치료하는 방법
|
|
FI3618875T3
(fi)
|
2017-05-02 |
2023-07-04 |
Novartis Ag |
Raf-inhibiittoria ja trametinibia käsittävä yhdistelmähoito
|
|
AR111960A1
(es)
|
2017-05-26 |
2019-09-04 |
Incyte Corp |
Formas cristalinas de un inhibidor de fgfr y procesos para su preparación
|
|
UY37866A
(es)
|
2017-09-07 |
2019-03-29 |
Glaxosmithkline Ip Dev Ltd |
Nuevos compuestos derivados de benzoimidazol sustituidos que reducen la proteína myc (c-myc) en las células e inhiben la histona acetiltransferasa de p300/cbp.
|
|
WO2019053617A1
(en)
|
2017-09-12 |
2019-03-21 |
Glaxosmithkline Intellectual Property Development Limited |
CHEMICAL COMPOUNDS
|
|
CA3081602A1
(en)
|
2017-11-16 |
2019-05-23 |
Novartis Ag |
Combination therapies
|
|
AU2019239404B2
(en)
|
2018-03-19 |
2021-12-23 |
Taiho Pharmaceutical Co., Ltd. |
Pharmaceutical composition including sodium alkyl sulfate
|
|
WO2019180141A1
(en)
|
2018-03-23 |
2019-09-26 |
Bayer Aktiengesellschaft |
Combinations of rogaratinib
|
|
AU2019246719B2
(en)
|
2018-03-30 |
2022-06-16 |
Novartis Ag |
A triple pharmaceutical combination comprising dabrafenib, trametinib and an Erk inhibitor
|
|
EP3560516A1
(en)
|
2018-04-27 |
2019-10-30 |
Bergen Teknologioverforing AS |
Combination therapy including beta-sitosterol in combination with at least one of a braf inhibitor, a mek inhibitor or an erk inhibitor and methods and use thereof
|
|
CN112867716B
(zh)
|
2018-05-04 |
2024-09-13 |
因赛特公司 |
Fgfr抑制剂的固体形式和其制备方法
|
|
AU2019262579B2
(en)
|
2018-05-04 |
2024-09-12 |
Incyte Corporation |
Salts of an FGFR inhibitor
|
|
JOP20200303A1
(ar)
|
2018-05-24 |
2020-11-23 |
Janssen Biotech Inc |
عوامل ربط psma واستخداماتها
|
|
AR116109A1
(es)
|
2018-07-10 |
2021-03-31 |
Novartis Ag |
Derivados de 3-(5-amino-1-oxoisoindolin-2-il)piperidina-2,6-diona y usos de los mismos
|
|
JP2022504905A
(ja)
|
2018-10-16 |
2022-01-13 |
ノバルティス アーゲー |
標的化療法に対する応答を予測するためのバイオマーカーとしての単独の又は免疫マーカーと組み合わせた腫瘍突然変異負荷
|
|
CN109320513B
(zh)
*
|
2018-11-09 |
2021-03-16 |
安庆奇创药业有限公司 |
一种合成曲美替尼的方法
|
|
AU2019383311B2
(en)
|
2018-11-20 |
2024-12-05 |
Nflection Therapeutics, Inc. |
Cyanoaryl-aniline compounds for treatment of dermal disorders
|
|
EP3883567A4
(en)
*
|
2018-11-20 |
2022-07-27 |
NFlection Therapeutics, Inc. |
NAPHTHYRIDINONE ANILINE COMPOUNDS FOR THE TREATMENT OF SKIN DISEASES
|
|
IL283487B2
(en)
|
2018-11-30 |
2024-07-01 |
Glaxosmithkline Ip Dev Ltd |
Compounds useful in hiv therapy
|
|
EP3897637A1
(en)
|
2018-12-20 |
2021-10-27 |
Novartis AG |
Dosing regimen and pharmaceutical combination comprising 3-(1-oxoisoindolin-2-yl)piperidine-2,6-dione derivatives
|
|
WO2020161654A1
(en)
*
|
2019-02-06 |
2020-08-13 |
Aurobindo Pharma Limited |
A process for the preparation of trametinib acetic acid solvate
|
|
JP7488826B2
(ja)
|
2019-02-15 |
2024-05-22 |
ノバルティス アーゲー |
置換３－（１－オキソイソインドリン－２－イル）ピペリジン－２，６－ジオン誘導体及びその使用
|
|
JP7483732B2
(ja)
|
2019-02-15 |
2024-05-15 |
ノバルティス アーゲー |
３－（１－オキソ－５－（ピペリジン－４－イル）イソインドリン－２－イル）ピペリジン－２，６－ジオン誘導体及びその使用
|
|
US11628162B2
(en)
|
2019-03-08 |
2023-04-18 |
Incyte Corporation |
Methods of treating cancer with an FGFR inhibitor
|
|
KR20220002899A
(ko)
|
2019-04-19 |
2022-01-07 |
얀센 바이오테크 인코포레이티드 |
항-psma/cd3 항체로 전립선암을 치료하는 방법
|
|
MX2021013817A
(es)
|
2019-05-13 |
2021-12-14 |
Novartis Ag |
Nuevas formas cristalinas de n-(3-(2-(2-hidroxietoxi)-6-morfolinop iridin-4-il)-4-metilfenil)-2-(trifluorometil)isonicotinamida como inhibidores de raf para el tratamiento del cancer.
|
|
WO2021007269A1
(en)
|
2019-07-09 |
2021-01-14 |
Incyte Corporation |
Bicyclic heterocycles as fgfr inhibitors
|
|
WO2021018112A1
(zh)
*
|
2019-07-29 |
2021-02-04 |
江苏恒瑞医药股份有限公司 |
一种1，6-二氢吡啶-3-甲酰胺衍生物的制备方法
|
|
WO2021018941A1
(en)
|
2019-07-31 |
2021-02-04 |
Glaxosmithkline Intellectual Property Development Limited |
Methods of treating cancer
|
|
US12122767B2
(en)
|
2019-10-01 |
2024-10-22 |
Incyte Corporation |
Bicyclic heterocycles as FGFR inhibitors
|
|
PH12022550892A1
(en)
|
2019-10-14 |
2023-05-03 |
Incyte Corp |
Bicyclic heterocycles as fgfr inhibitors
|
|
US11566028B2
(en)
|
2019-10-16 |
2023-01-31 |
Incyte Corporation |
Bicyclic heterocycles as FGFR inhibitors
|
|
CA3163875A1
(en)
|
2019-12-04 |
2021-06-10 |
Incyte Corporation |
Tricyclic heterocycles as fgfr inhibitors
|
|
CA3162010A1
(en)
|
2019-12-04 |
2021-06-10 |
Incyte Corporation |
Derivatives of an fgfr inhibitor
|
|
IL293889A
(en)
|
2019-12-20 |
2022-08-01 |
Novartis Ag |
Uses of anti-tgf-beta antibodies and checkpoint inhibitors for the treatment of proliferative diseases
|
|
US20230381180A1
(en)
*
|
2020-01-08 |
2023-11-30 |
Icahn School Of Medicine At Mount Sinai |
Small molecule modulators of ksr-bound mek
|
|
WO2021146424A1
(en)
|
2020-01-15 |
2021-07-22 |
Incyte Corporation |
Bicyclic heterocycles as fgfr inhibitors
|
|
US20230226030A1
(en)
|
2020-02-18 |
2023-07-20 |
Novartis Ag |
Therapeutic combinations comprising a raf inhibitor for use in treating braf mutant nsclc
|
|
EP4134081A4
(en)
|
2020-04-10 |
2024-05-01 |
Taiho Pharmaceutical Co., Ltd. |
CANCER THERAPY USING 3,5-DISUBSTITUTED ALCYNYL BENZENE COMPOUND AND MEK INHIBITOR
|
|
US20230218644A1
(en)
|
2020-04-16 |
2023-07-13 |
Som Innovation Biotech, S.A. |
Compounds for use in the treatment of viral infections by respiratory syndrome-related coronavirus
|
|
CN115551509A
(zh)
|
2020-05-12 |
2022-12-30 |
诺华股份有限公司 |
包含craf抑制剂的治疗组合
|
|
AU2021285032A1
(en)
*
|
2020-06-02 |
2022-12-08 |
Boehringer Ingelheim International Gmbh |
Annulated 2-amino-3-cyano thiophenes and derivatives for the treatment of cancer
|
|
IL298262A
(en)
|
2020-06-23 |
2023-01-01 |
Novartis Ag |
Dosing regimen comprising 3-(1-oxoisoindolin-2-yl)piperidine-2,6-dione derivatives
|
|
WO2022043955A1
(en)
|
2020-08-31 |
2022-03-03 |
Novartis Ag |
Combination therapy of a raf inhibitor and a mek inhibitor for the treatment of sarcoma
|
|
WO2022120353A1
(en)
|
2020-12-02 |
2022-06-09 |
Ikena Oncology, Inc. |
Tead inhibitors and uses thereof
|
|
EP4255895A1
(en)
|
2020-12-02 |
2023-10-11 |
Ikena Oncology, Inc. |
Tead inhibitors and uses thereof
|
|
CA3205726A1
(en)
|
2021-01-25 |
2022-07-28 |
Alfredo C. Castro |
Combination of a 3-(imidazol-4-yl)-4-(amino)-benzenesulfonamide tead inhibitor with an egfr inhibitor and/or mek inhibitor for use in the treatment of lung cancer
|
|
WO2022162518A2
(en)
|
2021-01-28 |
2022-08-04 |
Janssen Biotech, Inc. |
Psma binding proteins and uses thereof
|
|
CN117794929A
(zh)
|
2021-02-02 |
2024-03-29 |
法国施维雅药厂 |
选择性bcl-xl protac化合物及使用方法
|
|
JP2024511373A
(ja)
|
2021-03-18 |
2024-03-13 |
ノバルティス アーゲー |
がんのためのバイオマーカーおよびその使用
|
|
TWI825637B
(zh)
*
|
2021-03-31 |
2023-12-11 |
美商輝瑞股份有限公司 |
啶－１，６（２ｈ，７ｈ）－二酮
|
|
TW202304979A
(zh)
|
2021-04-07 |
2023-02-01 |
瑞士商諾華公司 |
抗ＴＧＦβ抗體及其他治療劑用於治療增殖性疾病之用途
|
|
EP4319757A1
(en)
|
2021-04-09 |
2024-02-14 |
Boehringer Ingelheim International GmbH |
Anticancer therapy
|
|
JP2024513575A
(ja)
|
2021-04-12 |
2024-03-26 |
インサイト・コーポレイション |
Ｆｇｆｒ阻害剤及びネクチン－４標的化剤を含む併用療法
|
|
CA3215081A1
(en)
*
|
2021-04-16 |
2022-10-20 |
Alfredo C. Castro |
Mek inhibitors and uses thereof
|
|
EP4333847A1
(en)
|
2021-05-05 |
2024-03-13 |
Novartis AG |
Compounds and compositions for the treatment of mpnst
|
|
AR125874A1
(es)
|
2021-05-18 |
2023-08-23 |
Novartis Ag |
Terapias de combinación
|
|
WO2022259157A1
(en)
|
2021-06-09 |
2022-12-15 |
Novartis Ag |
A triple pharmaceutical combination comprising dabrafenib, trametinib and a shp2 inhibitor
|
|
AR126102A1
(es)
|
2021-06-09 |
2023-09-13 |
Incyte Corp |
Heterociclos tricíclicos como inhibidores de fgfr
|
|
WO2023114984A1
(en)
|
2021-12-17 |
2023-06-22 |
Ikena Oncology, Inc. |
Tead inhibitors and uses thereof
|
|
WO2023166345A2
(en)
|
2022-03-02 |
2023-09-07 |
Novartis Ag |
Precision therapy for the treatment of cancer
|
|
CN114605408B
(zh)
*
|
2022-03-30 |
2023-06-16 |
沈阳药科大学 |
5-羟基-1,3-二取代苯基吡啶并[2,3-d]嘧啶类化合物及其制法和应用
|
|
CN114573582B
(zh)
*
|
2022-03-30 |
2023-06-16 |
沈阳药科大学 |
1,2,3,4-四氢吡啶并[2,3-d]嘧啶类化合物及其制备方法和应用
|
|
CN114456166B
(zh)
*
|
2022-03-30 |
2023-06-16 |
沈阳药科大学 |
5-取代氨基-3-甲基吡啶并[2,3-d]嘧啶类化合物及其制备与应用
|
|
CN114573581B
(zh)
*
|
2022-03-30 |
2023-09-01 |
沈阳药科大学 |
5-取代氨基-1,3-二取代苯基吡啶并[2,3-d]嘧啶类化合物及其制备与应用
|
|
WO2023225320A1
(en)
|
2022-05-20 |
2023-11-23 |
Novartis Ag |
Epha2 bcl-xl inhibitor antibody-drug conjugates and methods of use thereof
|
|
WO2023225336A1
(en)
|
2022-05-20 |
2023-11-23 |
Novartis Ag |
Met bcl-xl inhibitor antibody-drug conjugates and methods of use thereof
|
|
CN114853754B
(zh)
*
|
2022-05-23 |
2023-04-18 |
云白药征武科技(上海)有限公司 |
一种硫代酰胺衍生物及其制备方法和应用
|
|
CN119768393A
(zh)
|
2022-05-25 |
2025-04-04 |
医肯纳肿瘤学公司 |
Mek抑制剂和其用途
|
|
AR129423A1
(es)
|
2022-05-27 |
2024-08-21 |
Viiv Healthcare Co |
Compuestos útiles en la terapia contra el hiv
|
|
WO2024189481A1
(en)
|
2023-03-10 |
2024-09-19 |
Novartis Ag |
Panras inhibitor antibody-drug conjugates and methods of use thereof
|
|
CN118121604B
(zh)
*
|
2024-05-07 |
2024-06-25 |
四川成都中农大现代农业产业研究院 |
表没食子儿茶素没食子酸酯的组合物及其作为铜离子载体抗肝癌增敏剂的用途
|